Medicinal plants used in the treatment of tuberculosis - Ethnobotanical and ethnopharmacological approaches.

Antimycobacterial agents Evidence-based medicine Herbal medicine Multi drug-resistance Mycobacterium Traditional healing systems

Journal

Biotechnology advances
ISSN: 1873-1899
Titre abrégé: Biotechnol Adv
Pays: England
ID NLM: 8403708

Informations de publication

Date de publication:
15 11 2020
Historique:
received: 29 12 2016
revised: 22 06 2017
accepted: 05 07 2017
pubmed: 9 9 2020
medline: 13 1 2021
entrez: 8 9 2020
Statut: ppublish

Résumé

Tuberculosis is a highly infectious disease declared a global health emergency by the World Health Organization, with approximately one third of the world's population being latently infected with Mycobacterium tuberculosis. Tuberculosis treatment consists in an intensive phase and a continuation phase. Unfortunately, the appearance of multi drug-resistant tuberculosis, mainly due to low adherence to prescribed therapies or inefficient healthcare structures, requires at least 20 months of treatment with second-line, more toxic and less efficient drugs, i.e., capreomycin, kanamycin, amikacin and fluoroquinolones. Therefore, there exists an urgent need for discovery and development of new drugs to reduce the global burden of this disease, including the multi-drug-resistant tuberculosis. To this end, many plant species, as well as marine organisms and fungi have been and continue to be used in various traditional healing systems around the world to treat tuberculosis, thus representing a nearly unlimited source of active ingredients. Besides their antimycobacterial activity, natural products can be useful in adjuvant therapy to improve the efficacy of conventional antimycobacterial therapies, to decrease their adverse effects and to reverse mycobacterial multi-drug resistance due to the genetic plasticity and environmental adaptability of Mycobacterium. However, even if some natural products have still been investigated in preclinical and clinical studies, the validation of their efficacy and safety as antituberculosis agents is far from being reached, and, therefore, according to an evidence-based approach, more high-level randomized clinical trials are urgently needed.

Identifiants

pubmed: 32896577
pii: S0734-9750(20)30131-2
doi: 10.1016/j.biotechadv.2020.107629
pii:
doi:

Substances chimiques

Anti-Infective Agents 0
Antitubercular Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

107629

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Javad Sharifi-Rad (J)

Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: javad.sharifirad@gmail.com.

Bahare Salehi (B)

Medical Ethics and Law Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: bahar.salehi007@gmail.com.

Zorica Z Stojanović-Radić (ZZ)

Department of Biology and Ecology, Faculty of Science and Mathematics, University of Niš, Višegradska 33, Niš, Serbia.

Patrick Valere Tsouh Fokou (PVT)

Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra LG 581, Ghana; Antimicrobial Agents Unit, LPMPS, Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé 812, Cameroon.

Marzieh Sharifi-Rad (M)

Department of Chemistry, Faculty of Science, University of Zabol, Zabol, Iran.

Gail B Mahady (GB)

Department of Pharmacy Practice, Clinical Pharmacognosy Laboratories, University of Illinois at Chicago, USA.

Majid Sharifi-Rad (M)

Department of Range and Watershed Management, Faculty of Natural Resources, University of Zabol, Zabol, Iran.

Mohammad-Reza Masjedi (MR)

Tobacco Control Strategic Research Center, Shahid Beheshti University of Medical Sciences Tehran, Iran.

Temitope O Lawal (TO)

Department of Pharmacy Practice, Clinical Pharmacognosy Laboratories, University of Illinois at Chicago, USA; Department of Pharmaceutical Microbiology, University of Ibadan, Ibadan, Nigeria.

Seyed Abdulmajid Ayatollahi (SA)

Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Pharmacognosy, School of Pharmacy, Shahid Beheshti University of Medical Sciences Tehran, Iran.

Javid Masjedi (J)

Tobacco Control Strategic Research Center, Shahid Beheshti University of Medical Sciences Tehran, Iran.

Razieh Sharifi-Rad (R)

Department of Biology, Faculty of Science, University of Zabol, Zabol, Iran.

William N Setzer (WN)

Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA.

Mehdi Sharifi-Rad (M)

Department of Medical Parasitology, Zabol University of Medical Sciences, 61663335 Zabol, Iran. Electronic address: mehdi_sharifirad@yahoo.com.

Farzad Kobarfard (F)

Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Iran.

Atta-Ur Rahman (AU)

H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan.

Muhammad Iqbal Choudhary (MI)

H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan.

Athar Ata (A)

Department of Chemistry, Richardson College for the Environmental Science Complex The University of Winnipeg, Winnipeg, Canada.

Marcello Iriti (M)

Department of Agricultural and Environmental Sciences, Milan State University, via G. Celoria 2, Milan 20133, Italy. Electronic address: marcello.iriti@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH